Efficacy and safety of mifepristone for the treatment of psychotic depression

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 436-440

  Blasey, Christine M ^a   Block, Thaddeus S ^a   Belanoff, Joseph K ^a   Roe, Robert L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cortisol; glucocorticoid receptor antagonists; hypothalamic pituitary adrenal axis; mifepristone; psychotic depression; ROC analyses; signal detection

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIFEPRISTONE; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; ASTHMA; CONTROLLED STUDY; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTRITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; PLEURA EFFUSION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SUICIDAL IDEATION;

ADULT; DEPRESSIVE DISORDER; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; MIFEPRISTONE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 79960612871     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182239191     Document Type: Article

References (26)

1. Coryell W, Pfohl B, Zimmerman M. The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis. 1984;172(9): 521-528. (Pubitemid 14019613)
2. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry. 2002;159(11):1855-1861. (Pubitemid 35283250)
3. Vythilingham M, Chen J, Bremner JD, et al. Psychotic depression and mortality. Am J Psychiatry. 2003;160(3):574-576. (Pubitemid 41094270)
4. Johnson J, Horwath E,Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry. 1991;48:1075-1081.
5. Coryell W, Leon A, Winokur G, et al. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry. 1996;153(4):483-489. (Pubitemid 26113311)
6. Aronson TA, Shukla S, Gujavarty K, et al. Relapse in delusional depression: a retrospective study of the course of treatment. Compr Psychiatry. 1988;29(1):12-21. (Pubitemid 18035423)
7. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149(6):733-745.
8. Lattuada E, Serretti A, Cusin C, et al. Symptomatologic analysis of psychotic and non-psychotic depression. J Affect Dis. 1999;54: 183-187. (Pubitemid 29287688)
9. Guadiano BA, Beevers CG, Miller IW. Differential response to combined treatment in patients with psychotic versus nonpsychotic major depression. J Nerv Ment Dis. 2005;193(9):625-628. (Pubitemid 41298365)
10. Kantor SJ, Glassman AH. Delusional depressions: natural history and response to treatment. Br J Psychiatry. 1977;131:351-360. (Pubitemid 8188569)
11. Duval F, Mokrani M, Monreal-Ortiz J, et al. Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates. Psychoneuroendocrinology. 2006;31:876-888. (Pubitemid 44202373)
12. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry. 1997;154(11):1497-1503. (Pubitemid 27471341)
13. Keller J, Flores B, Gomez RG, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry. 2006;60:275-281. (Pubitemid 44093438)
14. Belanoff JK, Flores B, Kalezhan M, et al. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001;21:516-521. (Pubitemid 32937434)
15. Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52:386-392. (Pubitemid 35266729)
16. DeBattista C, Belanoff JK, Glass S, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry. 2006;60:1343-1349. (Pubitemid 44838535)
17. Flores B, Kenna H, Keller J, et al. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31:628-636. (Pubitemid 43276978)
18. Simpson GM, El Sheshai A, Loza N, et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry. 2005;66(5):598-602. (Pubitemid 40733702)
19. Blasey CM, DeBattista C, Roe R, et al. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp Clin Trials. 2009;30(4):284-288.
20. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812.
21. Kraemer HC. Evaluating Medical Tests. Newbury Park, CA: Sage; 1992.
22. Glassman AH, Roose SP. Delusional depression, a distinct clinical entity? Arch Gen Psychiatry. 1981;38:424-427. (Pubitemid 11156027)
23. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840- 1847. (Pubitemid 34303629)
24. Brogden RN, Goa KL, Faulds D. Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1993;45(3):384-409. (Pubitemid 23104125)
25. Baptista T, De Mendoza S, Beaulieu S, et al. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Dis. 2004;2(4):290-307. (Pubitemid 40846902)
26. Grigoletti L, Perini G, Rossi A. Mortality and cause of death among psychiatric patients: a 20-year case-register study in an area with a community-based system of care. Psychol Med. 2009;39:1875-1884.